Persistence of de novo donor‐specific HLA‐antibodies after lung transplantation: A potential marker of decreased patient survival
Authors:
Abstract
The impact of de novo donor‐specific anti‐HLA‐antibodies (donor‐specific antibody [DSA]) on outcomes in lung transplantation is still a matter of debate. We hypothesize that differentiating DSA by persistent and transient appearance may offer an additional risk assessment. The clinical relevance of HLA‐antibodies was investigated prospectively in 72 recipients with a median follow‐up period of 21 months. The presence of HLA‐antibodies was analysed by a single antigen bead assay before and after (3 weeks, 3, 6, 12 and 18 months) transplantation. In 23 patients (32%), de novo DSAs were detected. In 10 of these patients (44%), DSA persisted throughout the follow‐up period, whereas 13 of these patients (56%) had transient DSA. There was a trend towards lower 1‐year‐survival in DSA‐positive compared with DSA‐negative patients (83% vs 94%; P = 0.199). Remarkably, patients with persistent DSA had significantly reduced survival (1‐year survival 60%) compared with both patients without DSA and those with transient DSA (P = 0.005). Persistent DSA represented as an independent prognostic factor for reduced overall survival in multivariate analysis (HR 8.3, 95% CI 1.8‐37.0; P = 0.006). Persistence of DSA during the first year after transplantation seems to be more harmful for lung allograft function than transiently detected DSA at an early stage.Keywords
Funding Information
- the German Center for Lung Research (DZL) (DZL No. 82DZL66302)
This publication has 26 references indexed in Scilit:
- The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft FailureThe Journal of Heart and Lung Transplantation, 2015
- Bronchiolitis obliterans syndrome due to donor‐specific HLA‐antibodiesTissue Antigens, 2015
- A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2015
- De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantationThe Journal of Heart and Lung Transplantation, 2014
- De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantationThe Journal of Heart and Lung Transplantation, 2014
- Early donor-specific antibodies in lung transplantation: Risk factors and impact on survivalThe Journal of Heart and Lung Transplantation, 2014
- Implications for Human Leukocyte Antigen Antibodies After Lung TransplantationChest, 2013
- Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantationThe Journal of Heart and Lung Transplantation, 2013
- The Munich‐LTX‐Score: predictor for survival after lung transplantationClinical Transplantation, 2011
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantationThe Journal of Heart and Lung Transplantation, 2010